Piramal Pharma Ltd. has completed the purchase of an additional 40.67% stake in Yapan Bio Private Limited for ₹76 crore, or $7.95 million, lifting its ownership to 74% and converting the Hyderabad-based vaccines and biologics manufacturer from an associate into a subsidiary. The deal, finalized on August 18, 2026, deepens Piramal's push into biologics by bringing Yapan Bio's process development, characterization, and Phase I and II GMP (good manufacturing practice) manufacturing services into its wider contract development and manufacturing network. The company said Yapan Bio will continue to operate within Piramal Pharma Solutions, where its capabilities also support ADCelerate™, a fixed-price platform for Phase I ADC (antibody-drug conjugate) development from R&D to GMP in as little as 12 months.